The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer

被引：72

作者：

Oguri, Tetsuya

Achiwa, Hiroyuki

Muramatsu, Hideki

Ozasa, Hiroaki

Sato, Shigeki

Shimizu, Shigeki

Yamazaki, Hideko

Eimoto, Tadaaki

Ueda, Ryuzo

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Mizuho Ku, Nagoya, Aichi 4678601, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Pathol, Mizuho Ku, Nagoya, Aichi 4678601, Japan

来源：

CANCER LETTERS | 2007年 / 256卷 / 01期

关键词：

hENT1; immunohistochemistry; gemcitabine; NSCLC;

D O I：

10.1016/j.canlet.2007.06.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report here the development of a polyclonal antibody for human equilibrative nucleoside transporter 1 (hENT1) and assess the expression of hENT1 in non-small cell lung cancer (NSCLC) patients who were treated with gemcitabine-containing chemotherapy. hENT1 expression was analyzed by immunohistochemical staining in 24 NSCLC biopsy samples of formalin-fixed, paraffin-embedded tissues. The hENT1-positive staining in NSCLC samples was significantly associated with response to gemcitabine-containing chemotherapy. Responses to gemcitabine-containing chemotherapy were evident in none of the seven patients with no hENT1 expression. These results indicate that the absence of hENT1 expression may be useful to predict NSCLC patients who will not respond to gemcitabine-containing chemotherapy. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：112 / 119

页数：8

共 22 条

[1] Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer [J].

Achiwa, H ;

Oguri, T ;

Sato, S ;

Maeda, H ;

Niimi, T ;

Ueda, R .

CANCER SCIENCE, 2004, 95 (09) :753-757

[2] Nucleoside transporters: molecular biology and implications for therapeutic development [J].

Baldwin, SA ;

Mackay, JR ;

Cass, CE ;

Young, JD .

MOLECULAR MEDICINE TODAY, 1999, 5 (05) :216-224

[3] RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer [J].

Bepler, Gerold ;

Kusmartseva, Irina ;

Sharma, Swati ;

Gautam, Ashish ;

Cantor, Alan ;

Sharma, Anupama ;

Simon, George .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4731-4737

[4]

Dabbagh L, 2003, CLIN CANCER RES, V9, P3213

[5] Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors [J].

Farré, X ;

Guillén-Gómez, E ;

Sánchez, L ;

Hardisson, D ;

Plaza, Y ;

Lloberas, J ;

Casado, FJ ;

Palacios, J ;

Pastor-Anglada, M .

INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (06) :959-966

[6]

García-Manteiga J, 2003, CLIN CANCER RES, V9, P5000

[7] Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine [J].

Giovannetti, E ;

Del Tacca, M ;

Mey, V ;

Funel, N ;

Nannizzi, S ;

Ricci, S ;

Orlandini, C ;

Boggi, U ;

Campani, D ;

Del Chiaro, M ;

Iannopollo, M ;

Bevilacqua, G ;

Mosca, F ;

Danesi, R .

CANCER RESEARCH, 2006, 66 (07) :3928-3935

[8]

Goh LB, 1995, ANTICANCER RES, V15, P2575

[9] Nucleoside and nucleobase transport systems of mammalian cells [J].

Griffith, DA ;

Jarvis, SM .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON BIOMEMBRANES, 1996, 1286 (03) :153-181

[10] Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs [J].

Griffiths, M ;

Beaumont, N ;

Yao, SYM ;

Sundaram, M ;

Boumah, CE ;

Davies, A ;

Kwong, FYP ;

Coe, I ;

Cass, CE ;

Young, JD ;

Baldwin, SA .

NATURE MEDICINE, 1997, 3 (01) :89-93

← 1 2 3 →